Extrawell Pharmaceutical Holdings Limited provided unaudited consolidated earnings guidance for the year ended 31 March 2023. For the year, Group expects to record a loss of about HKD 190 million as compared to a profit for the year ended 31 March 2022, which was primarily attributable to a non-cash item, resulted from a loss of about HKD 165 million arising from the fair value change of the Group's investments in convertible bonds, while a gain of about HKD 169 million due to the fair value change of the same non-cash item was incurred last year.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.041 HKD | 0.00% | -8.89% | +20.59% |
2023 | Extrawell Pharmaceutical Swings to Fiscal H1 Loss on Fair Value Losses | MT |
2023 | Extrawell Pharmaceutical Holdings Limited Reports Earnings Results for the Half Year Ended September 30, 2023 | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+20.59% | 12.54M | |
+38.59% | 727B | |
-7.89% | 347B | |
+15.66% | 319B | |
+0.24% | 274B | |
+13.21% | 238B | |
+7.18% | 204B | |
-6.26% | 203B | |
+4.23% | 161B | |
-1.70% | 160B |
- Stock Market
- Equities
- 858 Stock
- News Extrawell Pharmaceutical Holdings Limited
- Extrawell Pharmaceutical Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 March 2023